Congestive Heart Failure News and Research

RSS

Congestive Heart Failure is a condition in which the heart can't pump blood the way it should. In some cases, the heart can't fill with enough blood. In other cases, the heart can't send blood to the rest of the body with enough force. Some people have both problems. "Heart failure" doesn't mean that your heart has stopped or is about to stop working. However, it's a serious condition that requires medical care. Heart failure develops over time as the pumping of the heart grows weaker. It can affect the right side of the heart only or both the left and right sides of the heart. Most cases involve both sides of the heart.

Transitional and progressive care can help patients achieve functional recovery faster in post-acute care

Transitional care has emerged as a way to reduce hospital readmissions, and progressive care nurses can play an integral role in efforts to help patients achieve functional recovery faster in post-acute care, according to an article in the June issue of Critical Care Nurse.

3 Jun 2015

$Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma$

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).

1 Jun 2015

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma.

30 May 2015

Patient characteristics may guide TKI use in CML

The likelihood of complications associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukaemia may be reduced by considering patient factors and differences in the toxicity profiles of the different drug options, a review suggests.

29 May 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015.

28 May 2015

Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced an upcoming poster presentation regarding its lead drug candidate, aldoxorubicin, at the 2015 American Society of Clinical Oncology Annual Meeting, which is being held May 29 - June 2, 2015 in Chicago.

27 May 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19.

17 May 2015

Study finds botulinum toxin injections in epicardial fat pads reduce AF risk immediately following surgery and after one year of follow-up

AF is the most common arrhythmia complicating cardiac surgery and occurs in approximately 30-40 percent of patients undergoing CABG surgery...

15 May 2015

New predictive analytics model identifies congestive heart failure patients with high readmission risk

Readmission of patients with chronic diseases is a growing problem, costing the U.S. health care system about $25 billion each year. Researchers at The University of Texas at Dallas developed a predictive analytics model that can identify congestive heart failure patients with high readmission risk and potentially help stymie those costs.

15 May 2015

Kaiser Permanente, Intermountain Healthcare to participate in U.S. News Hospital Outcome Data Disclosure Program

U.S. News & World Report, publisher of Best Hospitals and Best Children's Hospitals, today announced that Kaiser Permanente and Intermountain Healthcare will participate in the U.S. News Hospital Outcome Data Disclosure Program, a new data-collection initiative designed to evaluate hospitals more completely and give patients better information about the hospitals in their communities.

7 May 2015

Intervention to connect low-income uninsured patients to primary care could improve health, reduce costs

An intervention to connect low-income uninsured and Medicaid patients to a reliable source of primary health care shows promise for reducing avoidable use of hospital emergency departments in Maryland. A University of Maryland School of Public Health study evaluating the results of the intervention was published this week in the May issue of the journal Health Affairs.

6 May 2015

Global market for cardiac rhythm management devices worth $13 billion for 2015

The global market for cardiac rhythm management devices such as pacemakers and defibrillators is worth about $13 billion for 2015, according to Kalorama Information. The market research publisher said the market has benefited from the demand to move to a more mobile, wireless and efficient system both within major health facilities and in the home treatment markets. There is also an increasing trend to upgrade to more portable devices and devices which have added benefits such as MRI compatibility.

29 Apr 2015

MGH researchers find probable mechanism associated with risk of developing serious diseases

Massachusetts General Hospital investigators have found the probable mechanism underlying a previously described biomarker associated with the risk of developing serious diseases ranging from cancer to cardiovascular disease and the risk of serious complications. In a paper published in the American Journal of Hematology, the research team reports finding that higher levels of a measure routinely taken as part of the complete blood count - the extent of variation in the size of red blood cells - is caused by reduced clearance of aging cells from the bloodstream.

20 Apr 2015

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.

13 Apr 2015

Cardio3 BioSciences announces successful completion of futility analysis for C-Cure

Cardio3 BioSciences, a leader in engineered cell therapy treatments, today announced the successful completion of a futility analysis for C-Cure, its lead cell therapy for congestive heart failure, currently being evaluated in a Phase III clinical trial in Europe and Israel (CHART-1).

31 Mar 2015

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira, Inc., a global leader in biosimilars and the world's leading provider of injectable drugs and infusion technologies, announces the availability of INFLECTRA (infliximab) in Canada, the country's first subsequent entry biologic (SEB) monoclonal antibody (mAb) therapy.

30 Mar 2015

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy.

30 Mar 2015

Penn surgeons develop new tools to identify joint replacement patients at risk for serious complications

Orthopedic surgeons from the Perelman School of Medicine at the University of Pennsylvania have developed two new prediction tools aimed at identifying total hip and knee replacement patients who are at-risk of developing serious complications after surgery.

30 Mar 2015

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

Cardio3 BioSciences, a leader in the discovery and development of engineered cell therapies, today confirmed plans to open a new U.S.-based manufacturing facility in Rochester, Minnesota. The facility will support the Company’s current and anticipated manufacturing needs in the United States for both the Phase III clinical trial evaluating lead cardiovascular product candidate C-Cure (CHART-2), and its recently acquired CAR T-cell therapies’ portfolio.

26 Mar 2015

New drug fails to prevent irreversible injury to the heart after angioplasty

Patients who received the new drug Bendavia before undergoing angioplasty or receiving a stent to clear blocked arteries after a heart attack showed no significant reduction in scarring as compared to patients given a placebo, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session.

18 Mar 2015

Congestive Heart Failure News and Research

Transitional and progressive care can help patients achieve functional recovery faster in post-acute care

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Patient characteristics may guide TKI use in CML

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

Study finds botulinum toxin injections in epicardial fat pads reduce AF risk immediately following surgery and after one year of follow-up

New predictive analytics model identifies congestive heart failure patients with high readmission risk

Kaiser Permanente, Intermountain Healthcare to participate in U.S. News Hospital Outcome Data Disclosure Program

Intervention to connect low-income uninsured patients to primary care could improve health, reduce costs

Global market for cardiac rhythm management devices worth $13 billion for 2015

MGH researchers find probable mechanism associated with risk of developing serious diseases

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Cardio3 BioSciences announces successful completion of futility analysis for C-Cure

Hospira announces availability of INFLECTRA (infliximab) in Canada

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Penn surgeons develop new tools to identify joint replacement patients at risk for serious complications

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

New drug fails to prevent irreversible injury to the heart after angioplasty

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News